Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 346

Results For "C"

9223 News Found

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
Drug Approval | January 03, 2024

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals


Strides Pharma Science to invest in AMP-6, AMP-8
News | January 03, 2024

Strides Pharma Science to invest in AMP-6, AMP-8

AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka


Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
News | January 03, 2024

Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India

Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs


Healthcare Triangle completes US$2 million private placement debt offering
Digitisation | January 03, 2024

Healthcare Triangle completes US$2 million private placement debt offering

The company received gross proceeds of approximately US$1.7 million and net proceeds,


WuXi XDC partners with IntoCell to accelerate ADC discovery and development
News | January 03, 2024

WuXi XDC partners with IntoCell to accelerate ADC discovery and development

IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate


Dr. Reddy's acquires MenoLabs
News | January 03, 2024

Dr. Reddy's acquires MenoLabs


Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData
News | January 02, 2024

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year


Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
News | January 02, 2024

Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)


Enpro to acquire Advanced Micro Instruments
News | January 02, 2024

Enpro to acquire Advanced Micro Instruments

AMI to become part of Enpro’s Sealing Technologies Segment


Inspira Technologies closes on $3.88 million RDO
News | January 02, 2024

Inspira Technologies closes on $3.88 million RDO

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering